Liverpool and Leeds, United Kingdom
Antigen-specific T cells have been cloned from the peripheral blood of hypersensitive patients and characterized in terms of cellular phenotype and function to understand the cellular pathophysiology of different forms of hypersensitivity reactions. [1] [2] [3] [4] Data derived from these studies indicated that delayed-type hypersensitivity reactions could be categorized according to the phenotype of drug-specific T cells, the cytokines they secrete, and pathways of immune-mediated killing of target cells. 5 Essentially, reactions were divided into 4 subsets. In the last decade, our knowledge of the mechanistic basis of drug hypersensitivity has increased exponentially. For example, we now know that (1) herpes virus reactivation is implicated in certain reactions, 6, 7 (2) HLA allele expression is an important determinant for susceptibility, 8, 9 and (3) specific forms of druginduced kidney and liver injury should fall under the definition of drug hypersensitivity. [10] [11] [12] [13] Despite this, our knowledge of the T cells that instigate and/or regulate drug hypersensitivity reactions has not progressed significantly in the last decade.
The cytokine milieu to which naive T cells are exposed at the time of antigen exposure and during differentiation is known to determine the nature of the antigen-specific response and the types of secretory molecules that can affect tissue cells. In recent years, memory CD4
1 and CD8 1 T cells have been shown to secrete distinct cytokine signatures: T H 1 (IFN-g), T H 2 (IL-4, IL-5, and IL-13), T H 17 (IL-17 and IL-22), and T H 22 . However, the picture is complicated somewhat because the cytokines IL-17 and IL-22 can also be secreted by T H 1/T H 2 T cells.
14,15 IL-22 is thought to be of particular importance in allergic skin disease because receptors to which the cytokine binds are expressed on epithelial cells, including keratinocytes. 16 Moreover, T H 17-and T H 22-secreting T-cell subsets tend to express chemokine receptors that promote skin migration (eg, CCR4 and CCR10). 17 As human skin is protected by discrete populations of resident and recirculating T cells, 18 we have isolated and cloned drug-specific T cells from the blood and skin of hypersensitive patients and characterized their cellular phenotype and function after antigen recall to determine whether IL-17, IL-22, or both participate in drug hypersensitivity reactions. Previous studies with human T cells isolated from the memory T-cell pool have shown a mixed cytokine pattern with small shifts in balance toward a dominant cytokine. Thus our patient studies were conducted in parallel to T-cell priming experiments using PBMCs from healthy volunteers and a recently described dendritic cell/T-cell coculture system. 19 This assay is simple to manipulate, which allowed us to assess the influence of aryl hydrocarbon (ArH) receptor signaling on the nature of the primary drug-specific response.
Piperacillin hypersensitivity was selected as the study model for several reasons. First, piperacillin is a b-lactam antibiotic, and antibiotic hypersensitivity is the most common form of drug-induced allergic disease. Second, piperacillin forms drug antigens directly in patients and in vitro through the selective covalent modification of lysine residues on proteins, such as human serum albumin. 20 Third, piperacillin is a commonly prescribed drug, and the frequency of hypersensitivity has been estimated to be as high as 35% in patients with cystic fibrosis. 21 Finally, PBMC and blood-derived T-cell clones have been shown to be activated in vitro in the presence of piperacillin and piperacillin albumin conjugates. 22 
METHODS

Human subjects and cell isolation/separation
Venous blood (20-60 mL) was collected from 4 piperacillin-hypersensitive patients with cystic fibrosis and 4 control subjects who had been exposed to at least 1 course of piperacillin with no recorded adverse events. PBMCs were isolated and used for the lymphocyte transformation test, generation of EBV-transformed B cells, and T-cell cloning. Punch biopsy samples (3 mm) were obtained from 2 of the hypersensitive patients (patients 1 and 2) after a positive 24-hour intradermal skin test result. The intravenous preparation of piperacillin-tazobactam (Tazocin; Wyeth Pharmaceuticals, Berkshire, United Kingdom) was used for intradermal testing at a concentration of 2 mg/mL. A volume of 0.02 mL was injected with a 0.5-mm 3 16-mm insulin needle, which created an injection wheal of around 3 mm. Between 24 and 48 hours, an infiltrated erythema of more than 5 mm was seen, and a punch biopsy was performed. Skin was broken up with a scalpel and cultured in medium containing IL-2 (100 IU/mL) for 5 days. T cells migrating into culture medium were collected, passed through a 50-mm strainer, and used for T-cell cloning.
PBMCs were also isolated from 120 mL of blood from 4 healthy volunteers to study the priming of naive T cells with piperacillin. Monocytes and naive T-cell populations were separated with magnetic microbeads (Miltenyi Biotech, Bisley, United Kingdom).
CD14
1 cells were positively selected from total PBMCs. For isolation of naive T cells, pan-negative T-cell separation was performed with an anti-T-cell antibody cocktail. CD3 1 cells were then subjected to positive selection to remove the unwanted CD25 1 regulatory T cells and memory cells (CD45RO
1
). Naive T cells before priming were consistently greater than 98% pure. The purity of the CD14 1 monocytes varied depending on the level of neutrophil contamination in the PBMC preparation but was generally greater than 80%. Monocyte-derived dendritic cells were 100% positive for CD40, CD58, CD86, and class I and II expression.
Approval for the study was obtained from the Liverpool and Leeds local research ethics committees, and informed written consent was received from participants before inclusion in the study.
Medium for T-cell culture and cloning
Culture medium consisted of RPMI 1640 supplemented with pooled heat-inactivated human AB serum (10%, vol/vol), HEPES (25 mmol/L), L-glutamine (2 mmol/L), transferrin (25 mg/mL), streptomycin (100 mg/mL), and penicillin (100 U/mL). IL-2 (100 IU/mL) was added to establish drug-specific T-cell lines and clones.
Lymphocyte transformation test and PBMC ELISpot
PBMCs (1.5 3 10 5 cells/well) from hypersensitive patients and tolerant control subjects were incubated with piperacillin (0.5-4 mmol/L) or tetanus toxoid (5 mg/mL as a positive control) in culture medium for 5 days. Tritiated thymidine was added for the final 16 hours of the experiment. IFN-g-, IL-13-, IL-17-, and IL-22-secreting PBMCs were visualized with an ELISpot (MabTech, Nacka Strand, Sweden) by culturing PBMCs (5 3 10 5 cells/well) in culture medium with piperacillin (0.5-2 mmol/L) for 48 hours.
Priming of naive T cells from healthy volunteers
CD14
1 monocytes were cultured for 8 days in culture medium containing GM-CSF and IL-4 (800 U/mL) to generate dendritic cells. On day 7, TNF-a (25 ng/mL) and LPS (1 mg/mL) were added to induce maturation. Mature dendritic cells (0.8 3 10 5 cells/well; total volume, 2 mL) were cultured with CD3 1 CD25 2 CD45RO 2 naive T cells (2.5 3 10 6 cells/well) and piperacillin (2 mmol/L) or nitroso sulfamethoxazole (50 mmol/L; used as a positive control) in a 24-well plate for 7 days. The experiment was repeated after inclusion of (1) TGF-b (5 ng/mL), IL-1b (10 ng/mL), and IL-23 (20 ng/mL) to polarize the induction protocol toward a T H 17 phenotype or TNF-a (50 ng/mL) and IL-6 (20 ng/mL) to polarize toward a T H 22 phenotype and (2) the ArH receptor agonist VAF347 (50 nmol/L) or ArH receptor antagonist (CH-223191) 100 nmol/L; Millipore, Watford, United Kingdom).
Primed T cells (1 3 10 5 cells/well) were restimulated with dendritic cells (4 3 10 3 cells/well) and either piperacillin (0.5-2 mmol/L) or nitroso sulfamethoxazole (12.5-50 mmol/L). After 48 hours, proliferative responses and cytokine release were measured with tritiated thymidine and IFN-g, IL-13, IL-17, or IL-22 ELISpot, respectively.
Generation of EBV-transformed B cells
EBV-transformed B-cell lines were generated from PBMCs and used as antigen-presenting cells in experiments with T-cell clones.
Generation of drug-specific T-cell clones
PBMCs (1-5 3 10 6 /mL) from hypersensitive patients were incubated with piperacillin (2 mmol/L) in IL-2-containing medium to establish drug-responsive T-cell lines. After 14 days, T cells were serially diluted (0.3-3 cells/well) and subjected to PHA-driven expansion (5 mg/mL). 4 cells/well) for 48 hours in triplicate cultures per experimental conditions. Proliferation was measured by the addition of tritiated thymidine, followed by scintillation counting. Clones with a stimulation index (mean counts per minute of drug-treated wells/mean counts per minute in control wells) of greater than 2 were expanded and analyzed further.
T cells from inflamed patient skin and healthy volunteer PBMCs after priming were cloned by using the same procedure. Dose-dependent proliferative responses and profiles of secreted cytokines (IFN-g, IL-13, granzyme B, Fas ligand (FasL), perforin, IL-17, and IL-22) were measured by using tritiated thymidine and ELISpot, respectively. The ELISpot reader accurately counts spots up to approximately 400, thus providing an upper limit to the assay. Not all T cells in a clonal population are capable of responding. There are several reasons for this: (1) T-cell receptor (TCR) stimulation and costimulation must be optimal; (2) the level/form of antigen presented by individual antigen-presenting cells might not be optimal; (3) some of the T cells might not interact with antigen-presenting cells; and (4) the ability of the T cell to respond depends on the cell being in resting stage or G 0 of the cell cycle. Thus preliminary experiments were conducted to optimize cell numbers. Eventually, T-cell clones ( Approximately 1 ) and piperacillin (2 mmol/L) for 24 hours. GolgiStop was added for the last 4 hours of culture. Cells were then fixed and permeabilized with the BD Cytofix/Cytoperm Kit (BD Biosciences) and incubated with anti-cytokine antibodies for 30 minutes on ice and washed once. All cells were acquired with a FACSCanto II (BD Biosciences, Oxford, UK), and data were analyzed by using Cyflogic. A minimum of 50,000 lymphocytes were acquired with forward-scatter/side-scatter characteristics. ELISA was conducted with human IFN-g, IL-13, and IL-22 Ready-SET-Go kits (eBioscience), according to the manufacturer's instructions.
Chemotaxis assays were performed with 5-mm pore-containing 24-well transwell plates. T cells (1 3 10 5 ) were added to the upper chambers and placed in medium containing different chemotactic molecules (CCL2, CCL4, CCL17, CCL25, CCL27, CXCL9, and CXCL16; 100 nmol/L). Time-dependent chemotactic migration was recorded with a hemocytometer at between 1 and 24 hours.
Statistics
All statistical analyses (1-way ANOVA unless stated otherwise) were performed with SigmaPlot 12 software (Systat Software, Chicago, Ill).
RESULTS
PBMCs from piperacillin-hypersensitive patients proliferate and secrete IFN-g, IL-13, and IL-22 after drug stimulation
PBMCs from 4 hypersensitive patients were stimulated to proliferate with piperacillin in a dose-dependent manner (0.25-4 mmol/L). At the optimal concentration of 2 mmol/L piperacillin, the stimulation index ranged from 20 to 62. Proliferative responses were also detected with the positive control tetanus toxoid (Fig 1, A) . In contrast, PBMCs from drug-tolerant control subjects proliferated in the presence of tetanus toxoid but not piperacillin (stimulation index <1.5; results not shown).
Cytokine secretion from piperacillin-stimulated hypersensitive patients' PBMCs were analyzed with ELISpot. Significant levels (P < .05) of IFN-g, IL-13, and IL-22 were secreted from piperacillin (and PHA)-treated cultures when compared with cultures containing medium alone (Fig 1, B) . Although PHA treatment of hypersensitive patients' PBMCs was associated with secretion of IL-17, piperacillin-specific IL-17 secretion was not detected. however, drug-specific CD8 1 clones were isolated from each patient. Proliferative responses were concentration dependent, with optimal responses detected using a concentration of 2 mmol/L piperacillin (results not shown). After expansion of the clones, 43 CD4
1 and CD8 1 well-growing clones randomly selected from the 4 patients were used for analysis of cytokine secretion. Clones expressed single but varied TCR Vb chains.
Activation of the clones with piperacillin resulted in secretion of IFN-g, IL-13, and IL-22; however, IL-17 was not detected (Fig 1, E) . Clones were also isolated from the skin of hypersensitive patients 1 and 2 after a positive intradermal test result. Ninety-six piperacillin-responsive clones were generated from a total of 690 tested (response rate, 13.9%; Fig 2, A and B) . Analogous to the experiments with PBMCs, the majority of drug-specific clones were CD4
1 . Twenty-four well-growing clones were selected for analysis of cytokine secretion. Drug treatment was associated with release of IFN-g, IL-13, and IL-22 but not IL-17 (Fig 2, C) . PBMC and T-cell clones from blood of hypersensitive patients proliferate and secrete IFN-g, IL-13, and IL-22 when stimulated with piperacillin. A, PBMCs from hypersensitive patients were cultured with piperacillin for 5 days at 378C. Tritiated thymidine was added for the final 16 hours to measure PBMC proliferation. B, PBMCs from hypersensitive patients were cultured with piperacillin for 2 days at 378C. Cytokine secretion was visualized by using ELISpot. Images from 2 representative patients are shown. C, The table shows the number of piperacillin-responsive T-cell clones generated from blood of hypersensitive patients and their CD phenotype. D, T-cell clones were cultured with irradiated antigen-presenting cells and piperacillin, and proliferative responses were measured. E, T-cell clones were cultured with irradiated antigenpresenting cells and piperacillin, and cytokine secretion was quantified. *P < .05. sfu, Spot-forming units. Chemokine receptor expression on piperacillin-specific T-cell clones derived from blood and inflamed skin of hypersensitive patients. Piperacillin-specific T-cell clones derived from the blood and skin of hypersensitive patients were analyzed for chemokine receptor expression by using flow cytometry. The box plot shows medians and 25th/75th percentiles, with error bars showing 10th/90th percentiles. E-CAD, E-cadherin; MFI, median fluorescence intensity. *P < .05
and skin-derived clones. However, with the skin-derived clones, the response was much more polarized, and clones secreting low-to-moderate levels of cytokines were rarely seen. Fig 3, B, shows mean levels of IL-22 secretion from individual clones. Fig 3, C, Skin-derived piperacillin-specific clones secrete perforin, granzyme B, and FasL Clones derived from blood (n 5 24) and skin (n 5 24) secreted high levels of granzyme B (Fig 3, D) . However, significantly higher levels of perforin and FasL were detected from the piperacillin-treated skin-derived clones. Interestingly, piperacillin-specific CD4 1 clones secreted the highest levels of FasL and perforin (Fig 3, E) .
Chemokine receptor expression on piperacillinspecific T-cell clones
Expression of 12 chemokine receptors, CLA, CD69, and E-cadherin were compared on piperacillin-specific blood-and skin-derived clones (n 5 24-36 per group). Piperacillin-specific blood-and skin-derived clones expressed high levels of CD69 (see Fig E4 in this article' s Online Repository at www.jacionline.org). Skin-derived clones that were not activated with piperacillin were used as an additional comparator. Piperacillin-specific skin-and blood-derived clones were found to express multiple chemokine receptors, including CCR4, CCR5, CCR8, CCR9, and CCR10 and CXCR1, CXCR3, and CXCR6 when flow cytometric data were analyzed as median fluorescence intensity (Fig 4) or percentage of positive cells (see Fig E5 in this article' s Online Repository at www.jacionline.org). Skin-derived piperacillin-specific clones expressed significantly higher levels of CCR1 and CLA compared with nonspecific clones. Blood-derived piperacillin-specific clones expressed higher levels of CCR9 when compared with the skin-derived piperacillin-specific and nonspecific clones. In contrast, CCR2, CXCR1, and CLA were expressed at higher levels on the piperacillin-specific skin-derived clones when the 2 populations of piperacillin-specific clones were compared (Fig 4 and see Fig E5) . No significant correlation between chemokine receptor expression and IL-22 secretion by piperacillin-stimulated clones was observed (see Fig E8 in this article' s Online Repository at www.jacionline.org). However, skin-and blood-derived IL-22-secreting clones had a tendency to express CCR4 and lower levels of CCR4, respectively.
All clones were found to migrate across transwell membranes in a time-dependent manner in the presence of the CCR4 and CCR10 ligands CCL17 and CCL27, respectively (Fig 5) . Furthermore, the blood-derived clones, which expressed significantly higher levels of CCR9, migrated in the presence of CCL25, a ligand for CCR9. Interestingly, all clones migrated to a similar extent, which suggests that threshold levels of chemokine receptor expression determine whether a clone will migrate in the presence of the relevant ligand.
Priming of naive T cells against piperacillin generates antigen-specific T H 22-secreting clones
Naive T cells from 4 volunteers were cultured in the presence of autologous monocyte-derived dendritic cells (CD11a   high   CD11c high CD14 2 CD80 high CD86 high MHC class II high ) and piperacillin for 8 days. Primed T cells were then cultured with a second batch of dendritic cells, and drug and antigen specificity was assessed. On restimulation, piperacillin concentrationdependent proliferative responses were clearly detectable (Fig 6, A) . The strength of the induced response was similar to that seen with cells from hypersensitive patients. Moreover, piperacillin-primed cells were not activated with the control antigen nitroso sulfamethoxazole. Similarly, nitroso sulfamethoxazole-primed T cells were not activated with piperacillin (results not shown).
Piperacillin stimulation of the primed cells resulted in secretion of IFN-g, IL-13, and IL-22, but IL-17 was not detected (Fig 6, B) . The priming experiment was repeated in the presence of cytokine cocktails known to polarize T cells toward T H 17 and T H 22 subsets. No qualitative difference in the profile of cytokines secreted from piperacillin-specific T cells was observed. In particular, IL-17 was not detected (results not shown).
Sixty-four piperacillin-responsive clones were generated from the 4 volunteers of a total of 526 tested (response rate, 12.2%; Fig 6, C and D) . Piperacillin-specific CD4 1 and CD8 1 clones were detected; however, in contrast to clones from hypersensitive patients, most expressed CD8 1 clones. Thirty-seven well-growing clones were tested and found to secrete IFN-g, IL-13, and IL-22, but not IL-17, after treatment with piperacillin (Fig 6, E) .
Analysis of the profile of cytokines secreted from individual clones revealed that most CD4 1 and CD8 1 clones secreted high levels of IFN-g (Fig 7, A) . The few clones that secreted high levels of IL-22 were all CD8 1 and did not secrete other cytokines (ie, IFN-g, IL-13, and IL-17; Fig 7, B-D) .
Signaling through the ArH receptor is critical for the generation of piperacillin-specific IL-22-secreting T cells perforin, granzyme B, and FasL after restimulation with piperacillin; however, IL-22 secretion was no longer detected (Fig 8) .
DISCUSSION
To develop an effective classification of drug hypersensitivity, one must identify factors that contribute to and discriminate between the spectrum of diseases that fall under that definition. Classifying by drug is not effective because most drugs associated with a high frequency of reactions cause a range of adverse events. Similarly, classifying by HLA risk alleles does not work because the same MHC molecule might predispose patients to different forms of hypersensitivity reactions (eg, HLA-B*57:01; abacavir hypersensitivity and flucloxacillin-induced liver injury). 23 The existing classification of delayed-type drug hypersensitivity categorizes reactions based on the phenotype and function of drug-specific T cells 5 ; however, new T-cell subsets have never been considered. With this in mind, the current study focused on IL-17 and IL-22 because these cytokines are now believed to be important mediators of allergic reactions in the skin 16, 24 but have not been studied extensively in the context of drug hypersensitivity. Piperacillin was selected as the study drug because b-lactam hypersensitivity is the most common form of allergic drug reaction. T cells were cloned from blood and inflamed skin of the same hypersensitive patients to obtain a detailed assessment of the drug-specific response. Furthermore, naive T cells from healthy volunteers were primed against piperacillin to study factors that govern the development of a drug-specific T-cell response.
The lymphocyte transformation test and PBMC ELISpot are used routinely for hypersensitivity diagnosis and to characterize the culprit drug. 25, 26 In agreement with our previous studies, 20, 22 PBMCs from hypersensitive patients, but not tolerant control subjects, were stimulated in the presence of piperacillin to proliferate and secrete the T H 1/T H 2 cytokines IFN-g and IL-13. Moreover, PBMCs from hypersensitive patients secreted high levels of IL-22, whereas IL-17 was not detected. However, IL-17 secretion was detected from mitogen-stimulated PBMCs. Thus its absence from drug-treated PBMCs suggests that piperacillin-specific IL-17-secreting T cells do not circulate in the peripheral blood of hypersensitive patients. The failure to detect piperacillin-specific responses from the tolerant patient group (and drug-naive donors) might relate to differences in the abundance of precursor cells at the time of drug exposure. Future studies should attempt to quantify the difference by using established culture methods. 27 More than 500 piperacillin-specific T-cell clones were generated to determine the source of the secreted cytokines; drug treatment was associated with secretion of T H 1 (IFN-g  high ),  T H 2 (IL-13 high ), or a mixed phenotype panel of cytokines (IFN-g high /IL-13 high ). Given that human skin is protected by skin-resident and recirculating T cells with distinct functional activity, 18 it was important to compare the piperacillin-specific blood-derived T cells with T cells isolated from inflamed skin. These comparative studies gained further credence when Gaide et al 28 demonstrated, using a mouse model of contact dermatitis, that skin-resident and central memory T cells derive from a common origin. The authors reported that skin-resident cells responded rapidly after antigen challenge, whereas central memory cells were recruited to the tissue more slowly to mediate a delayed response. Similar to the blood-derived clones, approximately 85% of piperacillin-responsive clones isolated from inflamed skin were CD4
1 , and drug treatment resulted in secretion of the same cytokines, namely IFN-g, IL-13, and IL-22 but not IL-17. Most of the skin-derived clones secreting IL-22 were of the T H 1 phenotype. IL-22 binds to receptors expressed on cells, such as keratinocytes, to mediate innate responses in the skin. Although IL-22 has been described as a protective cytokine, it also promotes pathogenic responses when secreted, as we have found, in the presence of other cytokines. 29 For example, CD4 1 and CD8 1 T cells that secrete IFN-g and IL-22 are implicated in the pathogenesis of chronic skin conditions, such as psoriasis. 30 Collectively, our data shows that IL-22 signaling participates in maculopapular drug eruptions; however, additional studies are required to delineate whether IL-22 acts to promote disease progression or alternatively to regulate the severity of tissue injury.
FasL, perforin, and granzyme B are T-cell secretory molecules that act in unison to induce apoptosis in tissue cells. Early studies by Posadas et al 31 reported upregulated levels of perforin and granzyme B in PBMCs isolated from patients with acute mild and severe forms of drug-induced skin injury. Moreover, a strong correlation was observed between the level of cytolytic molecules and severity of the disease. In contrast, FasL was only observed in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. More recently, Zawodiniak et al 32 used a granzyme B ELISpot to detect cytotoxic T cells in the blood of patients with various forms of drug-induced skin injury. Accordingly, we used drug-specific clones isolated from blood and skin of the same hypersensitive patients to measure and compare FasL, perforin, and granzyme B secretion. Blood-and skin-derived clones secreted high levels of granzyme B when activated with piperacillin, which to some extent explains the findings of Zawodiniak et al. 32 In contrast, secretion of perforin and FasL was largely restricted to the skin-derived clones. These data show that (1) drug-specific skin-resident T cells are the most likely mediators of tissue injury and (2) analysis of blood-derived T cells alone underestimates the importance of cytolytic molecules in disease pathogenesis.
A subset of T cells expressing the skin-homing chemokine receptors CCR4 and CCR10 have previously been shown to secrete IL-22 and hence are thought to be important mediators of skin pathophysiology. 33 Furthermore, ligands for CCR4 (CCL17) and CCR10 (CCL27), which contribute to recruitment of IL-22-secreting cells, have been found at high levels in the lesional skin of patients with atopic dermatitis. 34, 35 Thus the next component of our study was to characterize expression of chemokine receptors on blood-and skin-derived, piperacillin-specific, IL-22-secreting clones and to measure the migratory potential of the clones toward relevant chemokines. Blood and skin-derived CD4 1 and CD8 1 clones were found to express multiple chemokine receptors, including CCR4, CCR5, CCR8, CCR9, and CCR10 and CXCR1, CXCR3, and CXCR6. Interestingly, CLA was expressed in higher levels on the skin-derived clones. Comparison of chemokine receptor expression and IL-22 secretion revealed that skin-derived IL-22-secreting clones had a tendency to express higher levels of CCR4, and the opposite was true for blood-derived clones. Most importantly, both skin-and blood-derived clones migrated toward CCL17 and CCL27 (ie, ligands for the 2 chemokine receptors). Interestingly, blood-derived clones expressed high levels of CCR9, a receptor more traditionally associated with homing toward the gastrointestinal tract, 36 and migrated in the presence of the CCR9 ligand CCL25, which suggests that drug-specific T cells in blood have the capacity to migrate to different locations around the body.
Cell-culture platforms have been developed in recent years to study the priming of naive T cells against chemical and drug antigens. 19, 37, 38 In these assays naive T cells from healthy donors are cultured with autologous dendritic cells and the chemical/drug for 7 to 14 days. The newly primed T cells are then restimulated with a second batch of dendritic cells and a range of compounds to assess antigen specificity. We used these methods to characterize the panel of cytokines secreted by naive T cells (from 4 healthy volunteers) primed against piperacillin. After restimulation, the piperacillin-primed cells proliferated vigorously and secreted IFN-g, IL-13, and IL-22. Importantly, IL-22 was seen in the absence of polarizing cytokines, such as IL-6 and TNF-a, which promote the differentiation of naive T cells into IL-22-secreting effectors. 33 T cells cloned from the piperacillin-primed naive T cells were skewed toward a CD8 1 phenotype, and drug stimulation resulted in secretion of high levels of IFN-g and low-to-moderate levels of IL-13 and IL-22. Analysis of individual clones revealed that the 3 clones secreting high levels of IL-22 were CD8
1 . They did not secrete T H 1 or T H 2 cytokines. Antigen-specific T cells with this phenotype are rarely reported in the literature, 16, 39 and their role in allergic disease needs to be investigated further. The reason why CD8 1 clones were detected at a high frequency from healthy volunteers is not clear but possibly relates to (1) differences in drug concentration during priming or (2) a different mechanism of drug presentation, as we recently reported with the b-lactam flucloxacillin. 11, 40 The transcription factor ArH receptor regulates the differentiation of naive T cells into IL-22-secreting cells. Selective ArH receptor antagonists have been shown to perturb the production of IL-22-secreting cells from naive precursors, whereas memory T cells are refractory to ArH receptor regulation. 41, 42 In the final component of the project, naive T cells were primed against piperacillin in the presence of an ArH receptor agonist (VAF347) and antagonist (CH-223191). T cells primed to piperacillin in the presence of VAF347 secreted IFN-g, IL-13, and IL-22 alongside the cytolytic molecules perforin, granzyme B, and FasL after restimulation with the drug. In parallel experiments with CH-223191, the differentiation of naive T cells into piperacillin-specific IL-22-secreting cells was blocked, whereas all other secretory molecules were detected at essentially the same level. Thus ArH receptor signaling is critical for the generation of drug-specific IL-22-secreting T cells.
In conclusion, our study shows that circulating and skin-resident CD4 1 and CD8 1 T cells that secrete IL-22, but not IL-17, alongside cytolytic molecules are important mediators of b-lactam hypersensitivity in human subjects. Differentiation of naive T cells into drug-specific IL-22-secreting cells is dependent on ArH receptor signaling. The reason why b-lactam hypersensitivity reactions are so common in patients with cystic fibrosis might relate to clinical practice: drugs are administered at high intravenous concentrations for a long duration and on a repeated basis. Moreover, enhanced risk might relate to the inflammatory response in patients with cystic fibrosis. The lungs of a patient with cystic fibrosis exist in a chronic acute responsive state with high numbers of neutrophils and cytokines, such as IL-8, IL-1b, IL-6, and TNF-a. In fact, the local cytokine environment might polarize the drug-specific T-cell response toward the T H 22 profile identified herein.
We thank the patients and volunteers for agreeing to donate blood and tissue samples. FIG E4. CD69 expression on piperacillin-specific T-cell clones derived from blood and inflamed skin of hypersensitive patients. Piperacillinspecific T-cell clones derived from blood and skin of hypersensitive patients (n 5 24-36 per group) were analyzed for CD69 expression by using flow cytometry. Skin-derived clones that were not piperacillin responsive were used as an additional comparator. For analysis, side-scatter profiles were plotted against CD69, and the percentage of cells expressing the receptor was recorded. The box plot shows the median and 25th/75th percentiles, with error bars showing the 10th/90th percentiles.
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FIG E5.
Chemokine receptor expression on piperacillin-specific T-cell clones derived from blood and inflamed skin of hypersensitive patients. Piperacillin-specific T-cell clones derived from blood and skin of hypersensitive patients (n 5 24-36 per group) were analyzed for chemokine receptor expression by using flow cytometry. Skin-derived clones that were not piperacillin responsive were used as an additional comparator. For analysis, side-scatter profiles were plotted against individual chemokine receptors, and the percentage of cells expressing the receptor was recorded. The box plot shows the median and 25th/75th percentiles, with error bars showing the 10th/90th percentiles. E-CAD, E-cadherin.
FIG E6.
Flow cytometric dot plot images showing chemokine receptor expression on a representative piperacillin-specific T-cell clone. A, T-cell clones were stained for surface markers by using directly conjugated antibodies. Median fluorescence intensity (MFI) was calculated for individual chemokine receptors, and data are presented in Fig 4. B, T-cell clones were stained for surface markers by using directly conjugated antibodies. For analysis, side-scatter profiles were plotted against individual chemokine receptors, and the percentage of cells expressing the receptor was recorded; data are presented in Fig E5 . Cells were incubated on ice for 20 minutes and then washed with 1 mL of 10% FCS in HBSS. All cells were acquired with a FACSCanto II flow cytometer, and data were analyzed by using Cyflogic. BL, Bottom left quadrant; BR, bottom right quadrant; TL, top left quadrant; TR, top right quadrant. 
FIG E8.
Comparison of chemokine receptor expression and IL-22 secretion on piperacillin-specific T-cell clones derived from blood and inflamed skin of hypersensitive patients. Piperacillin-specific T-cell clones derived from blood and skin of hypersensitive patients (n 5 24-36 per group) were analyzed for chemokine receptor expression by using flow cytometry. IL-22 secretion was measured by using ELISpot.
